Table 2.
Valuses are presented as mean±SD or % (n).
*There were 6 patients who received adalimumab due to persistent abdominal fistula and the baseline CDAI <150.
CR-70, decrease in CDAI of at least 70 points; CR-100, decrease in CDAI of at least 100 points; CR-150, decrease in CDAI of at least 150 points.